| 1 |
Development of next-generation cancer immunotherapy via FAP-targeted IL-12 attenuation-based TMEkineTM |
| Recombinant Protein |
Solid Tumor |
FAP, IL-12 |
Candidate |
KANAPH Therapeutics |
RS-2022-00166851 |
|
| 2 |
Non-clinical study and IND approval of GI-108, a metabolic immune anti-cancer drug |
| Recombinant Protein |
Solid Tumor |
CD73, IL-2 |
Preclinical |
GI Innovation, Inc |
RS-2022-00166700 |
|
| 3 |
Development of HER2-positive cancer treatment candidate through interferon-beta immunocytokine efficacy evaluation and production process research |
| Recombinant Protein |
HER2+ tumor |
IFN-β |
Candidate |
Genopharm Inc. |
RS-2022-00166539 |
|
| 4 |
Non-clinical development of long-acting IL-2 analog (HM16390) with optimized IL-2 receptor binding property |
| Recombinant Protein |
Renal cell carcinoma, melanoma |
IL-2 |
Preclinical |
Hanmi Pharm. Co., Ltd. |
RS-2022-00165557 |
|
| 5 |
Development of a treatment for refractory solid tumor targeting activated stellate cells |
| Recombinant Protein |
Solid tumor |
retinoid |
Lead |
Senelix |
HN22C0554 |
|
| 6 |
A Phase 1/2, open-label, dose-escalation, and expansion study to evaluate safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101 as a single agent and in combination with pembrolizumab, lenvatinib or local radiotherapy in patients with advanced or metastatic solid tumors (Keynote B59) |
| Recombinant Protein |
Advanced or Metastatic Solid Tumor |
CD80, IL-2 |
Phase 1 |
GI Innovation, Inc. |
HN22C0451 |
|
| 7 |
Development of CD47/CD73 dual-target SAFAbody antibody therapy for the treatment of intractable solid cancer including triple-negative breast cancer |
| Recombinant Protein |
TNBC |
CD47, CD73 |
Hit |
AprilBio |
HN22C0297 |
|
| 8 |
Development of ‘Best-in-Class’ IL-2 for Solid Tumor Treatments |
| Recombinant Protein |
Kidney cancer, Skin cancer |
IL-2 |
Hit |
Genuv |
HN21C1125 |
|
| 9 |
Efficacy and safety on anti-cancer drug candidate of immune-checkpoint protein and cytokine fused platform |
| Recombinant Protein |
Cancer |
IL-21, PD-1 |
Lead |
BIOnSYSTEMS |
HN21C1099 |
|
